valine has been researched along with dapagliflozin in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Boulton, DW; Chang, M; Griffen, SC; Kasichayanula, S; LaCreta, FP; Liu, X; Shyu, WC | 1 |
Fujita, Y; Furuya, F; Ikeda, K; Inagaki, N; Isomura, N; Kondo, A; Li, Y; Mano, F; Matsuo, N; Minamino, H; Oguri, Y; Takesue, K | 1 |
1 trial(s) available for valine and dapagliflozin
Article | Year |
---|---|
Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin.
Topics: Adult; Anti-Arrhythmia Agents; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Benzhydryl Compounds; Cross-Over Studies; Diabetes Mellitus, Type 2; Digoxin; Drug Interactions; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Simvastatin; Sodium-Glucose Transporter 2 Inhibitors; Tetrazoles; Valine; Valsartan; Warfarin | 2012 |
1 other study(ies) available for valine and dapagliflozin
Article | Year |
---|---|
Liver autophagy-induced valine and leucine in plasma reflect the metabolic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin.
Topics: Animals; Autophagy; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Glucose; Hypoglycemic Agents; Leucine; Liver; Mice; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters; Valine | 2022 |